HMR plans to cut outsourcing of clinical trials: new facility could allow 70% to be handled internally.
Executive Summary
HOECHST MARION ROUSSEL PLANS INCREASE OF INTERNAL TRIAL MANAGEMENT TO 50%-70% in a year and a half, HMR Assistant Director for Clinical Research, Planning & Coordination David Gillogly said at an Institute for International Research conference on "Cost Management for Clinical Trials" in Washington June 19. Following its move into a new facility 15 months ago, Hoechst plans to increase trial management staff to 150-160. Hoechst currently has a trial management staff of 110 and has outsourced 100% of its trials for the past two years, Gillogly said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth